Published in World J Gastroenterol on September 07, 2014
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer (2015) 1.10
MicroRNAs: Clinical Relevance in Colorectal Cancer. Int J Mol Sci (2015) 0.89
MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer. Biomed Res Int (2015) 0.88
Biological significance of long non-coding RNA FTX expression in human colorectal cancer. Int J Clin Exp Med (2015) 0.83
MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol (2016) 0.82
Gab2 is a novel prognostic factor for colorectal cancer patients. Int J Clin Exp Pathol (2015) 0.80
miR-183 regulates autophagy and apoptosis in colorectal cancer through targeting of UVRAG. Oncotarget (2016) 0.80
Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med (2016) 0.80
Biomarkers of Angiogenesis in Colorectal Cancer. Biomark Cancer (2015) 0.76
Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients. J Transl Med (2016) 0.76
Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells. BMC Cancer (2016) 0.75
miR-543 promotes colorectal cancer proliferation and metastasis by targeting KLF4. Oncotarget (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res (2003) 17.13
Processing of primary microRNAs by the Microprocessor complex. Nature (2004) 14.59
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Tumor angiogenesis. N Engl J Med (2008) 11.30
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A (2007) 5.50
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res (2009) 2.93
Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res (2008) 2.86
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol (2013) 2.67
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer (2008) 2.52
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer (2009) 2.45
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun (2008) 2.15
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
MicroRNAs in development and disease. Clin Genet (2008) 1.96
The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol (2008) 1.88
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res (2008) 1.80
MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J (2009) 1.54
miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle (2010) 1.51
Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg (2014) 1.46
microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng (2010) 1.44
miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther (2010) 1.42
Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett (2010) 1.42
Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron (2008) 1.37
Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res (2007) 1.37
MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ (2011) 1.33
The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One (2012) 1.26
miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol (2013) 1.24
Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther (2010) 1.20
Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer (2010) 1.20
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol (2002) 1.19
miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis (2013) 1.16
microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med (2011) 1.12
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol (2013) 1.10
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol (2009) 1.09
Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia (2012) 1.07
Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol (2012) 1.07
Overcoming resistance to antiangiogenic therapies. Oncologist (2012) 1.05
Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer (2008) 1.04
The role of microRNAs in breast cancer stem cells. Int J Mol Sci (2013) 1.04
Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer (2012) 1.04
Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g. Radiother Oncol (2013) 1.01
Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun (2013) 0.99
miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol (2013) 0.99
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer (2012) 0.98
MicroRNAs, ultraconserved genes and colorectal cancers. Int J Biochem Cell Biol (2009) 0.94
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist (2012) 0.93
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer (2013) 0.93
MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res (2012) 0.91
Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One (2013) 0.90
Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding. Clin Cancer Res (2013) 0.88
Comprehensive analysis of alterations in the miRNome in response to photodynamic treatment. J Photochem Photobiol B (2013) 0.88
EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS One (2013) 0.88
MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. Clin Colorectal Cancer (2013) 0.88
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res (2013) 0.88
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. Eur J Cancer (2010) 0.84
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol (2012) 0.81
Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma. Cancer Biol Med (2013) 0.78
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. Expert Opin Pharmacother (2013) 0.78